MIT PlasmoSniff pairs Bhatia nanoparticles with Tadesse Raman sensor for 10-minute exhaled biomarker detection

Bhatia lab nanoparticles release synthetic biomarkers only when cleaved by infection-specific proteases; healthy subjects exhale intact particles while infected lungs liberate detectable fragments. Tadesse group replaced bulky spectrometers with an enhanced surface-enhanced Raman platform that registers the fragments at concentrations previously requiring benchtop instruments. The 2020 mouse study in Nature Biomedical Engineering established proof-of-concept but left the sensor component unresolved. Garg et al. closed that gap by integrating the two subsystems into a single breath tube interface.

Portable Raman achieved 50-fold lower limit of detection than prior optical readouts while maintaining specificity across protease variants. This performance matches the threshold needed for exhaled samples diluted by tidal volume, a metric absent from earlier nanoparticle-only reports. Operationally the workflow requires one inhalation, a 10-minute circulation window, and a single exhalation into a handheld unit, eliminating sputum culture or chest imaging delays.

The architecture also supports non-medical use cases such as industrial solvent monitoring because the same protease-mimetic chemistry can be swapped for chemical-specific linkers. Regulatory path is shortened by the fact that nanoparticles have already completed rodent toxicology packages in Bhatia’s prior filings. Next milestone is a 50-patient human feasibility study using the integrated device, scheduled to begin Q1 2025 at two Boston-area clinics.

Tadesse lab projects first clinical prototype with integrated microfluidics and diode laser by late 2026, targeting 510(k) clearance within 18 months of that date if sensitivity holds above 92 percent in the human cohort.